ZK-283197

ZK-283197 (also known as BAY 86-5310 or SH-T04211C) is a selective and orally active ERβ agonist which was under development by Bayer Healthcare AG for the treatment of vasomotor symptoms.[1][2] It reached phase II clinical trials prior to the discontinuation of its development.[1] Its development was terminated in 2014.[1]

ZK-283197
Clinical data
Other namesBAY 86-5310; SH-T04211C
Routes of
administration		By mouth[1]
Drug classEstrogen; Selective ERβ agonist
Identifiers
CAS Number

References
  1. "ZK 283197 - AdisInsight". adisinsight.springer.com.
  2. US 14/332,204, Pietras, R. J., & Jung, M. E., "Methods of using estrogen receptor-beta ligands as radiation mitigators"


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.